Get started
Work

First-in-human study of ALK201, a FGFR2b-targeting antibody-drug conjugate (ADC) for patients (pts) with advanced solid tumors.

Year: 2026
Type: conference-abstract
DOI: 10.1200/jco.2026.44.16_suppl.3025
Authors: Dan-yun Ruan, Qi Dang, Suxia Luo, Yanqiu Zhao, Udit Nindra, Shou Qing Tang, Haiping Jiang, Jian Liu, Andrew Ohyama Parsonson, Michelle Frances Morris, Lin Xie, Xinjun Liang, Lilin Chen, Rui Meng, Sijuan Ding, Huaqiu Shi, Yong Fang, Meredith Pelster, Yongsheng Li, Rui-Hua Xu
Institutions: Sun Yat-sen University Cancer Center, Shandong First Medical University, Henan Cancer Hospital, University Medical Center New Orleans, First Affiliated Hospital Zhejiang University, Zhejiang University, Macquarie University, Sunshine Coast University Hospital, Hubei Cancer Hospital, First Affiliated Hospital of Xiamen University, Wuhan Union Hospital, Huazhong University of Science and Technology, Gannan Medical University, First Affiliated Hospital of Gannan Medical University, Sir Run Run Shaw Hospital, Sarah Cannon, Chongqing University, Chongqing Cancer Hospital
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7162531823
Cites:
Cited by:
Related to: